Jakob L.
- Country
- Denmark
- Department
- Dept Oncology, Phase I Unit
Research Overview
- A Phase 3 Randomized, Open-label Study of Opevesostat Tosylate Versus Abiraterone Acetate or Enzalutamide in Metastatic Castration-Resistant Prostate Cancer
- A Phase 3 Study of Xaluritamig versus Cabazitaxel or Second Androgen Receptor-Directed Therapy in Patients With Metastatic Castration-Resistant Prostate Cancer Previously Treated With Chemotherapy
Data & Insights
Has run more than one trial at 20 of 119 partner sites.
Specializations
Oncology Research
This investigator specializes in the treatment of metastatic castration resistant prostate cancer, focusing on evaluating innovative therapeutic approaches for advanced stages of the disease.
- Advanced Prostate Cancer Management
- Hormone-Resistant Disease Treatment
- Post-Chemotherapy Care
The investigator's work encompasses therapeutic strategies for patients who have progressed following conventional hormonal therapy and chemotherapy treatments.
Therapeutic Innovation
Primary research interests include the evaluation of novel therapeutic agents for prostate cancer treatment, with particular attention to comparative effectiveness against established treatment options.
- Novel Treatment Evaluation
- Comparative Therapy Assessment
- Treatment Resistance Studies
The investigator focuses on developing treatment pathways for patients with advanced disease states requiring alternative therapeutic approaches.
Clinical Outcomes
Research activities center on evaluating survival outcomes and disease progression in advanced prostate cancer patients, with emphasis on treatment efficacy assessment.
- Overall Survival Analysis
- Disease Progression Monitoring
- Treatment Response Assessment
The investigator's work includes comprehensive evaluation of therapeutic responses using established clinical assessment criteria.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.